All News

Advocacy fosters professional development, creates better working conditions, and enhances patient care.

Policymakers and health care providers call for reforms to improve transparency, pricing, and patient access.

Pharmacists play a crucial role in understanding and responding to these developments, ensuring patients remain informed about the latest advancements and potential threats.

The demands of the pharmacy profession—long hours, high stress, and emotional strain—can take a toll on pharmacists’ well-being.

Women living in rural are more likely to report experiencing psychological and somatic menopause symptoms compared with those in urban and suburban areas.

COVID-19 survivors deemed the most highly impacted and fearful also reported the lowest health-related quality of life scores, indicating an association.

The decline was attributed to continued adherence to infection prevention and control measures.

INTerpath-009 investigates the treatment for patients with resectable stage 2, 3A or 3B non–small cell lung cancer.

Less than 16% of high-risk lung cancer individuals have heard or discussed lung cancer screenings with a health care provider.

Oral semaglutide had a safe and well-tolerated profile for individuals with type 2 diabetes, which is in line with those previously reported for the drug in other trials.

Pharmacists will likely be the first contact for many affected patients, and they should be able to provide evidence-based advice on how to manage their infection.

Despite the new human case, which is not known to be related to animal exposure, the CDC emphasizes that risk to the general public remains low.

Bezisterim, an anti-inflammatory insulin sensitizer, will be authorized to proceed to a phase 2 clinical trial.

The researchers found that unusual and dramatic changes in weather as well as heavy rainfall helped aid in the pathogen’s evolutionary change.

The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

The CDC says that even if travel is less than 2 weeks away, unvaccinated individuals should still receive a dose of the measles, mumps, and rubella vaccine for protection against the disease.

The findings also demonstrate that body dysmorphic disorder is also associated with high levels of comorbid psychopathology, risk, and psychosocial impairment.

The authors emphasize that these findings suggest a need for targeted resources that help reduce boarding and promote equitable access to care.

Study shows that orange peel extract may reduce risk of heart disease and adverse cardiovascular events.

Reducing sodium intake is associated with decreased risk of atopic dermatitis (AD) and flares.

The authors note that this finding may have promise for use in assessing mental health conditions and improving patient outcomes.

The 5-in-1 meningococcal ABCWY vaccine candidate has an assigned Prescription Drug User Fee Act action date of February 14, 2025.

A study about modifiable risk factors on a “weak spot” in the brain network found that diabetes, pollution, and alcohol were most likely to contribute to dementia disorders.

The agency warns consumers against using these products, which are marketed for topical use to relieve pain associated with cosmetic procedures.

The efficacy data are consistent with other phase 3 studies, reinforcing lebrikizumab's potential as a first-line treatment across a range of skin tones.

The findings also indicated that individuals who experienced significant adverse events in childhood were approximately 17% more likely to experience adverse events in adulthood.

Children with normal weight had different community relationships compared to children with overweight or obesity.

The data follow the FDA approval of omalizumab for the reduction of allergic reactions, including anaphylaxis, that can occur after exposure to 1 or more foods.

This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.